EvaluatePharma

@evaluatepharma

EvaluatePharma is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2024 for the global life science industry.

London, Boston & Tokyo
Vrijeme pridruživanja: lipanj 2009.

Tweetovi

Blokirali ste korisnika/cu @evaluatepharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @evaluatepharma

  1. proslijedio/la je Tweet
    4. velj

    A big bet for : outcome studies of GLP-1 agonists in diabetes cost on avg $860m, and the huge CVOT for tirzepatide could set a new record. Check out our look at R&D cost estimates from :

    Poništi
  2. Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020:

    Poništi
  3. What are the interesting pharma pipeline deals to look out for in 2020?

    Poništi
  4. 5. velj

    The second half of 2019 saw half as many innovative medical devices approved as the first:

    Poništi
  5. 4. velj

    Thanks to several successful oncology franchises, is the pharma company with the biggest projected top-line growth in 2020. Download the Vantage 2020 Preview to learn more:

    Poništi
  6. 4. velj

    Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound:

    Poništi
  7. 4. velj

    Gilead has targeted the Wuhan coronavirus with remdesivir, resulting in its stock increasing 4%, but the omens from previous studies are not wholly positive (via ):

    Poništi
  8. 3. velj

    Ensure your 2020 plans have factored in the key risks and opportunities facing pharma this year. Download your free copy of the Vantage 2020 Preview for detailed analysis of the year ahead:

    Poništi
  9. 3. velj

    A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals:

    Poništi
  10. 3. velj

    Keytruda continues to be the marketed drug with the most expensive ongoing clinical programme, while oncology is the focus of most spending. Find out more in the Vantage 2020 Preview:

    Poništi
  11. 3. velj

    Evaluate is at the 5th Global Independent Research Conference in Wimpole Street today. Come and meet the team to understand how EvaluatePharma can enhance investment returns for buy-side.

    Poništi
  12. proslijedio/la je Tweet
    30. sij

    Huge move from with GIP/GLP-1 tirzepatide, to start 12,500 patient CVOT vs Trulicity, assessing non-inferiority and superiority. Surpass pivotal programme starts reporting later this year. Consensus for 2024 sales has been climbing, according to

    Poništi
  13. 31. sij
    Poništi
  14. 31. sij

    Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer:

    Poništi
  15. 31. sij

    What is the outlook for investment in pharma during 2020? Download your free copy of the Vantage 2020 Preview for the full analysis:

    Poništi
  16. 31. sij

    We're proud to announce we've been shortlisted for an Apprenticeship Connect Employer of the Year award 🥳. Thank you to all our current and past apprentices for their valuable contributions to life at Evaluate.

    Poništi
  17. proslijedio/la je Tweet
    31. sij
    Poništi
  18. proslijedio/la je Tweet
    29. sij

    Astra has spent a great deal on developing Brilinta, and it will take time to recoup that cost. Here, Vantage uses Vision data to estimate just how expensive the process has been.

    Poništi
  19. proslijedio/la je Tweet
    28. sij

    on Q4 call confirms anti-NGF tanezumab was filed with FDA in December, waiting for acceptance. Still sees "significant potential" in osteo arthritis. Sellside consensus virtually zero, according to , so a big wait and see here.

    Poništi
  20. 30. sij

    The amount of medtech venture capital deals has been declining significantly over the last decade:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·